Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity

Published:2017-03-16 Issue:2 Volume:151 Page:248-260
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Wallberg Maja¹^ORCID,Recino Asha¹,Phillips Jenny¹,Howie Duncan²,Vienne Margaux¹,Paluch Christopher¹,Azuma Miyuki³,Wong F. Susan⁴,Waldmann Herman²,Cooke Anne¹

Affiliation:

1. Department of Pathology; University of Cambridge; Cambridge UK

2. Sir William Dunn School of Pathology; University of Oxford; Oxford UK

3. Department of Molecular Immunology Graduate School; Tokyo Medical and Dental University; Tokyo Japan

4. Diabetes Research Group; Institute of Molecular and Experimental Medicine; Cardiff School of Medicine; Cardiff University; Cardiff UK

Funder

National Centre for the Replacement, Refinement and Reduction of Animals in Research

Diabetes UK

Diabetes Research and Wellness

H2020 European Research Council

Britain Israel Research and Academic Exchange Partnership (BIRAX)

Isaac Newton Trust

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imm.12729/fullpdf

Reference60 articles.

1. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice;Chatenoud;Proc Natl Acad Sci USA,1994

2. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus;Herold;N Engl J Med,2002

3. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial;Sherry;Lancet,2011

4. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes;Keymeulen;N Engl J Med,2005

5. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass;Keymeulen;Diabetologia,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altering β Cell Antigen Exposure to Exhausted CD8+ T Cells Prevents Autoimmune Diabetes in Mice;The Journal of Immunology;2024-04-08

2. Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation;The Journal of Immunology;2024-01-15

3. Developing Oncolytic Viruses for the Treatment of Cervical Cancer;Cells;2023-07-13

4. Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes;Recent Advances in Inflammation & Allergy Drug Discovery;2022-11-22

5. PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo;Cancers;2022-06-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3